Patents Assigned to University of Tennessee Research Foundation
  • Selective androgen receptor modulator and methods of use thereof
    Patent number: 10053418
    Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: August 21, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Duane D. Miller
  • Method and apparatus for providing random selection and long-term potentiation and depression in an artificial network
    Patent number: 10055434
    Abstract: A digital circuit element of a two dimensional dynamic adaptive neural network array (DANNA) may comprise a neuron/synapse select input functional to select the digital circuit element to function as one of a neuron and a synapse. In one embodiment of a DANNA array of such digital circuit elements, a destination neuron may be connected to a first neuron by a first synapse in one dimension, a second destination neuron may be connected to the first neuron by a second synapse in a second dimension and, optionally, a third destination neuron may be connected to the first neuron by a third synapse thus forming multiple levels of neuron and synapse digital circuit elements. In one embodiment, multiples of eight inputs may be selectively received by the digital circuit element selectively functioning as one of a neuron and a synapse.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 21, 2018
    Assignee: University of Tennessee Research Foundation
    Inventors: J. Douglas Birdwell, Mark E. Dean, Catherine Schuman
  • Mobile electric field sensor based phasor measurement unit for monitoring an electric power grid
    Patent number: 10024897
    Abstract: A system may include an electric field sensor, an analog to digital converter, and an estimator. The electric field sensor may measure electric fields of electric power grid. The analog to digital converter may generate digital output based upon measurements from the electric field sensor. The estimator may estimate phasor data of the electric power grid based upon the digital output.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: July 17, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Yilu Liu, Wenxuan Yao, Lingwei Zhan, Wei Gao, Haoyang Lu
  • Compounds for treatment of cancer
    Patent number: 10022356
    Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: July 17, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li
  • Selective androgen receptor degrader (SARD) ligands and methods of use thereof
    Patent number: 10017471
    Abstract: This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: July 10, 2018
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton, Yali He
  • Method and apparatus for constructing, using and reusing components and structures of an artifical neural network
    Patent number: 10019470
    Abstract: A method and apparatus for constructing a neuroscience-inspired artificial neural network (NIDA) or a dynamic adaptive neural network array (DANNA) or combinations of substructures thereof comprises one of constructing a substructure of an artificial neural network for performing a subtask of the task of the artificial neural network or extracting a useful substructure based on one of activity, causality path, behavior and inputs and outputs. The method includes identifying useful substructures in artificial neural networks that may be either successful at performing a subtask or unsuccessful at performing a subtask. Successful substructures may be implanted in an artificial neural network and unsuccessful substructures may be extracted from the artificial neural network for performing the task.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: July 10, 2018
    Assignee: University of Tennessee Research Foundation
    Inventors: J. Douglas Birdwell, Mark E. Dean, Catherine Schuman
  • SARMs and method of use thereof
    Patent number: 10010521
    Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 3, 2018
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Ramesh Narayanan, Thamarai Ponnusamy
  • Method for regulating retinal endothelial cell viability
    Patent number: 10010516
    Abstract: Here provided is a method for regulating retinal endothelial cell viability in a mammal by administering to the mammal a therapeutically effective amount of a quinic acid analog. The method may be applied to prevent, treat or cure pathological conditions of retinal endothelial cells associated with radiation retinopathy, diabetic retinopathy and chemotherapy for retinoblastoma.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: July 3, 2018
    Assignee: The University of Tennessee Research Foundation
    Inventors: Charles Ryan Yates, Jena Steinle Smith, Duane Douglas Miller, Jordan J. Toutounchian
  • Method and device for detection of bioavailable drug concentration
    Patent number: 9983162
    Abstract: The present invention is directed to an electrochemical sensor involving an electrode and a coating that surrounds the electrode, the coating comprising a structural component, a water immiscible solvent, a resistance decreasing component, and an ion exchange component, wherein the coating selectively partitions an electrochemically active drug from a fluid or vapor sample whereby an electrochemical signal within the coating can be measured using the electrode. Devices and methods for using this electrochemical sensor are also disclosed.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 29, 2018
    Assignees: THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
    Inventors: Edward Chaum, Erno Lindner, Jidong Guo
  • Compounds for treatment of cancer
    Patent number: 9981915
    Abstract: The present invention relates to colchicine-binding site compounds having anti-cancer activity, compositions comprising the same, and their use for treating various forms of cancer.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 29, 2018
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTx, INC
    Inventors: Yan Lu, James T Dalton, Wei Li, Duane D Miller
  • COMPOUNDS FOR TREATMENT OF CANCER
    Publication number: 20180118693
    Abstract: The present invention relates to colchicine-binding site compounds having anti-cancer activity, compositions comprising the same, and their use for treating various forms of cancer.
    Type: Application
    Filed: December 29, 2017
    Publication date: May 3, 2018
    Applicants: GTx, Inc., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Yan Lu, James T. Dalton, Wei Li, Duane D. Miller
  • Methods for gas-phase thermochromatographic separations of fission and activation products
    Patent number: 9951398
    Abstract: Methods are provided for characterizing samples containing chemical elements such as rare earth elements, actinides, and heavy transition metals by treating the samples to form volatile complexes of the elements (e.g., ?-diketonate complexes or other organic ligand complexes of the elements) and then analyzing the complexes, for example, via gas-phase thermochromatography. Also provided are methods for separating and/or recovering such chemical elements. The methods produce less waste and can be performed more rapidly than conventional liquid extraction methods and can provide separated elements of high purity (e.g., 99.9999% purity).
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: April 24, 2018
    Assignee: University of Tennessee Research Foundation
    Inventors: John D. Auxier, II, Daniel Hanson, Matthew L. Marsh, Howard L. Hall
  • MEMORY CELL COMPRISING COUPLED JOSEPHSON JUNCTIONS
    Publication number: 20180102166
    Abstract: Methods and apparatus are disclosed for operating a memory cell formed from the plurality of coupled Josephson junctions. The memory cell is configured such that applying an electrical signal to the junctions can cause at least one, but not all, of the junctions to change their respective phase states. Subsequent writes to the memory cell using substantially the same electrical pulse do not change the phase state of the plurality of junctions. The memory cell can be ready by providing another electrical pulse to one of the junctions and receiving an output electrical pulse generated in response by a different Josephson junction of the memory cell. A set of phase states are selected to represent the logic values that are stable across anticipated operating conditions for the memory cell. Methods of selecting electrical parameters and manufacturing memory cells are further disclosed.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 12, 2018
    Applicants: UT-Battelle, LLC, University of Tennessee Research Foundation
    Inventors: Yehuda Braiman, Neena Imam, Brendan Neschke
  • DUAL-FREQUENCY MODE TRANSMITTER FOR WIRELESS POWER TRANSFER
    Publication number: 20180097405
    Abstract: A transmitter for wireless power transfer is provided. The transmitter includes an input port, a first transmission port, a second transmission port, an inverter, and a controller. An input of the inverter is coupled to the input port, and an output of the inverter is coupled in parallel to the first and second transmission ports. The controller is programmed to control the inverter to modulate an output voltage at the output of the inverter such that power from the input port is transmitted at a first frequency through the first transmission port and at a second frequency through the second transmission port.
    Type: Application
    Filed: September 28, 2017
    Publication date: April 5, 2018
    Applicant: University of Tennessee Research Foundation
    Inventors: Daniel Jes COSTINETT, Chongwen ZHAO
  • Selective androgen receptor modulator for treating hormone-related conditions
    Patent number: 9889110
    Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: February 13, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Duane D. Miller
  • Selective androgen receptor modulator and methods of use thereof
    Patent number: 9884038
    Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: February 6, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy
  • Surface treated carbon catalysts produced from waste tires for fatty acids to biofuel conversion
    Patent number: 9884804
    Abstract: A method of making solid acid catalysts includes the step of sulfonating waste tire pieces in a first sulfonation step. The sulfonated waste tire pieces are pyrolyzed to produce carbon composite pieces having a pore size less than 10 nm. The carbon composite pieces are then ground to produce carbon composite powders having a size less than 50 ?m. The carbon composite particles are sulfonated in a second sulfonation step to produce sulfonated solid acid catalysts. A method of making biofuels and solid acid catalysts are also disclosed.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: February 6, 2018
    Assignees: UT-BATTELLE, LLC, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Zachary D. Hood, Shiba P. Adhikari, Marcus W. Wright, Abdessadek Lachgar, Yunchao Li, Amit K. Naskar, Mariappan Parans Paranthaman
  • Cross-linked polymeric membranes for carbon dioxide separation
    Patent number: 9873094
    Abstract: A membrane useful in gas separation, the membrane comprising a cross-linked polysiloxane structure having a cross-link density of about 0.1×10?5 mol/cm3 to about 6×10?5 mol/cm3, where, in particular embodiments, the cross-linked polysiloxane structure has the following general structure: wherein R1, R2, R3, R4, R5, and R6 are independently selected from hydrocarbon groups having at least 1 and up to 6 carbon atoms; A1 and A2 are independently selected from cyclic hydrocarbon groups; L1 and L2 are linking groups or covalent bonds; n is an integer of at least 1; r and s are independently selected from integers of at least 1; and p is an integer of at least 10. The invention also includes methods for making and using the above-described membranes for gas separation.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: January 23, 2018
    Assignees: UT-Battelle, LLC, University of Tennessee Research Foundation
    Inventors: Tao Hong, Sabornie Chatterjee, Shannon Mark Mahurin, Brian Keith Long, De-en Jiang, Jimmy Wayne Mays, Alexei P. Sokolov, Tomonori Saito
  • SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF
    Publication number: 20170368003
    Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 28, 2017
    Applicant: University of Tennessee Research Foundation
    Inventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE
  • SARMs and method of use thereof
    Patent number: 9844528
    Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 19, 2017
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Thamarai Ponnusamy, Ramesh Narayanan